Role of Pentoxifylline as an Adjuvant Therapy for Adult Patients With Major Depressive Disorder

Overview

This study aimed to evaluate the therapeutic benefits of pentoxifylline (PTX) in treatment of adult patients with MDD as it has anti-inflammatory and phosphodiastrase inhibition activities.

Full Title of Study: “Pentoxifylline as a New Adjuvant in Adult Patients With Major Depressive Disorder: Randomized, Double Blind, Placebo Controlled Trial.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: December 1, 2017

Detailed Description

In this study, the investigators evaluated the potential antidepressant effect of PTX in adult patients with MDD. the investigators hypothesized that MDD patients taking add-on PTX would present greater amelioration of their depressive symptoms than patients taking add-on placebo. Furthermore, the investigators assessed the relationship between HAM-D score and several peripheral biomarkers as well as their role in diagnosis and therapeutic targets of MDD.

Interventions

  • Drug: Escitalopram 20 mg tablet plus Pentoxifylline 400Mg Tablet
    • Selective serotonin reuptake inhibitor plus phosphodiesterase inhibitor with anti-inflammatory properties
  • Drug: Escitalopram 20 mg tablet + Placebo
    • Selective serotonin reuptake inhibitor plus placebo

Arms, Groups and Cohorts

  • Experimental: Pentoxifylline group
    • Escitalopram 20 mg tablet once daily for 12 week plus Pentoxifylline 400 mg tablet twice daily for 12 weeks
  • Placebo Comparator: Control group
    • Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet twice daily for 12 weeks

Clinical Trial Outcome Measures

Primary Measures

  • Effect on Hamilton Depression rating scale score (HAM-D score)
    • Time Frame: 12 week
    • The principal measure of the outcome was the 17-items HAM-D. Scoring is based on the 17-item scale and scores of 0-7 are considered as being normal, 8-13 suggest mild depression, 14-17 moderate depression and scores over 17 are indicative of severe depression. Remission is defined as HAM-D total score ≤ 7 (primary outcome). Treatment response is defined as ≥ 50% drop in the HAM-D total score.

Secondary Measures

  • Effect on biological markers
    • Time Frame: 12 week
    • Serum level of tumor necrosis factor alpha (TNF-α), Interleukin-6 (IL-6), Interleukin-10 (IL-10), brain derived neurotrophic factor (BDNF), 8-hydroxy-2′-deoxyguanosine (8-OHdG), and serotonin were measured at the baseline and after the treatment to evaluate the biological effects of the used medications.

Participating in This Clinical Trial

Inclusion Criteria

  • Eighty adult outpatients with the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of MDD based on a MINI Neuropsychiatric Interview (MINI) (American Psychiatric Association., 2000; Sheehan et al., 1998), without psychotic features and a total 17 item HAM-D score of at least 18 with item 1 (depressed mood) scored 2 or greater were eligible (Hamilton, 1960). – Patients were requested to be free of all the psychotropic and anti-inflammatory medications for at least 4 weeks before participating in the study. Exclusion Criteria:

  • Patients with bipolar I or bipolar II disorder – Patients with personality disorders – Patients with eating disorders – Patients with substance dependence or abuse – Patients with concurrent active medical condition – Patients with history of seizures – Patients with history of receiving Electroconvulsive therapy (ECT) – Patients with inflammatory disorders – Patients with allergy or contraindications to the used medications – Patients with finally pregnant or lactating females

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Mahmoud Samy Abdallah
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Mahmoud Samy Abdallah, Principal Investigator – Sadat City University
  • Overall Official(s)
    • Sahar El-Haggar, Ph.D, Study Director, Faculty of Pharmacy, Tanta University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.